Poor
Not Aligned
Patient Risk:
Moderate
Summary
None of the claims about Lipitor causing bleeding or bleeding-risk drug interactions are supported or contradicted by the provided FDA label excerpts. The only related label content provided mentions a hemorrhagic stroke signal at LIPITOR 80 mg, but the response does not correctly reference this label-specific context and instead makes broad claims about bleeding and specific antithrombotic drugs.
Category Scores
Accurate Statements
Unsupported Statements
Lipitor (atorvastatin) can cause bleeding as a potential side effect.
The provided label excerpts do not state that Lipitor can cause bleeding as a side effect. The only bleeding-related excerpt provided is a hemorrhagic stroke incidence comparison in the LIPITOR 80 mg group (Warnings 5.5), which is not the same as a general “bleeding” side effect statement.
Bleeding is a rare but serious side effect of Lipitor.
No provided label excerpt supports that “bleeding” is rare or explicitly classifies it as a serious side effect.
The risk of bleeding with statins, including Lipitor, increases when Lipitor is taken with other medications that also increase the risk of bleeding.
No provided label excerpt supports a general statement that coadministration with other bleeding-risk medications increases “bleeding risk” for Lipitor.
Warfarin increases the risk of bleeding when taken with Lipitor.
No provided label excerpt includes warfarin or a bleeding-risk interaction with warfarin.
Aspirin increases the risk of bleeding when taken with Lipitor.
No provided label excerpt includes aspirin or a bleeding-risk interaction with aspirin.
Clopidogrel increases the risk of bleeding when taken with Lipitor.
No provided label excerpt includes clopidogrel or a bleeding-risk interaction with clopidogrel.
Pentoxifylline increases the risk of bleeding when taken with Lipitor.
No provided label excerpt includes pentoxifylline or a bleeding-risk interaction with pentoxifylline.
Dipyridamole increases the risk of bleeding when taken with Lipitor.
No provided label excerpt includes dipyridamole or a bleeding-risk interaction with dipyridamole.
Taking Lipitor with medications that increase the risk of bleeding can increase levels of certain enzymes involved in blood clotting.
No provided label excerpt supports any claim that bleeding-risk co-medications increase “enzymes involved in blood clotting” with Lipitor.
The increased risk of bleeding is particularly relevant for patients taking anticoagulant medications.
No provided label excerpt supports that a bleeding risk is particularly relevant for anticoagulant use.
Contradictions
Low
AI Statement
A higher incidence of hemorrhagic stroke is seen in the LIPITOR 80 mg group compared to placebo.
Label Reference
Warnings 5.5 (provided): “...a higher incidence of hemorrhagic stroke was seen in the LIPITOR 80 mg group compared to placebo...”
Important Omissions
The response does not accurately contextualize the only provided bleeding-related label signal (higher incidence of hemorrhagic stroke in the LIPITOR 80 mg group vs placebo) and instead makes broad claims about bleeding.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Broad, unsupported bleeding-risk and specific anticoagulant/antiplatelet drug-interaction claims could mislead users about Lipitor’s bleeding risk profile and interaction management. However, no direct label-contradicting interaction information is provided; the primary issue is lack of support in the provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Unsupported broad “bleeding” adverse effect and unsupported specific drug-interaction claims (warfarin/aspirin/clopidogrel/pentoxifylline/dipyridamole) not present in the provided label excerpts; failure to correctly limit the only provided bleeding-related label signal to hemorrhagic stroke at LIPITOR 80 mg.
Suggested Improvement
Replace generalized bleeding-risk statements and specific anticoagulant/antiplatelet interaction claims with label-supported content only. If discussing bleeding risk, reference the provided Warnings 5.5 statement about hemorrhagic stroke incidence in the LIPITOR 80 mg group vs placebo, and omit unprovided drug-specific interaction claims.